TrialCurveSCOT: reconstructed Kaplan–Meier curves
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | J Clin Oncol. 2026 Jan 9;44(7):534–9. doi: 10.1200/JCO-25-00621 |
|---|---|
| DOI | 10.1200/JCO-25-00621 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Disease-free survival — Total study population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 2 years: 3 months 82%; 6 months 81%. Hazard ratio 3 months vs 6 months 0.97 (95% CI 0.88–1.07).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 3033 | 855 | not reached |
| 6 months | 3027 | 874 | not reached |
- 3 months vs 6 months: reconstructed HR 0.97 (95% CI 0.88–1.07)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 88.7% | 92.1% |
| 2 yr | 81.9% | 81.2% |
| 3 yr | 75.9% | 77.4% |
| 5 yr | 72.9% | 72.7% |
| 7 yr | 71.2% | 69.6% |
Checks against the published figure
- hazard ratio: printed 0.99, reconstructed 0.97 pass
Overall survival — Total study population
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 2 years: 3 months 94%; 6 months 94%. Hazard ratio 3 months vs 6 months 0.93 (95% CI 0.83–1.04).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 3035 | 601 | not reached |
| 6 months | 3029 | 639 | not reached |
- 3 months vs 6 months: reconstructed HR 0.93 (95% CI 0.83–1.04)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 97.4% | 97.6% |
| 2 yr | 94.5% | 93.8% |
| 3 yr | 91.0% | 89.5% |
| 5 yr | 82.3% | 82.4% |
| 7 yr | 78.2% | 76.9% |
Checks against the published figure
- hazard ratio: printed 0.96, reconstructed 0.932 pass
Survival after recurrence (SAR) — Patients with colorectal cancer recurrence, total study population
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 3 months 2.2 years; 6 months 2.0 years. Survival at 2 years: 3 months 56%; 6 months 51%. Hazard ratio 3 months vs 6 months 0.90 (95% CI 0.79–1.02).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 703 | 474 | 2.2 |
| 6 months | 701 | 492 | 2.0 |
- 3 months vs 6 months: reconstructed HR 0.90 (95% CI 0.79–1.02)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 76.7% | 71.6% |
| 2 yr | 55.6% | 50.8% |
| 3 yr | 41.0% | 35.6% |
| 5 yr | 25.7% | 23.8% |
| 7 yr | 19.4% | 15.3% |
Checks against the published figure
- hazard ratio: printed 0.9, reconstructed 0.899 pass
Overall survival — Patients treated with CAPOX
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 3 years: 3 months 91%; 6 months 89%. Hazard ratio 3 months vs 6 months 0.86 (95% CI 0.76–0.99).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 2051 | 406 | not reached |
| 6 months | 2042 | 466 | not reached |
- 3 months vs 6 months: reconstructed HR 0.86 (95% CI 0.76–0.99)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 100.0% | 97.4% |
| 2 yr | 100.0% | 93.3% |
| 3 yr | 91.2% | 89.1% |
| 5 yr | 83.3% | 81.2% |
| 7 yr | 77.4% | 75.2% |
| 10 yr | 67.6% | 57.6% |
Checks against the published figure
- hazard ratio: printed 0.9, reconstructed 0.863 pass
Overall survival — Patients treated with FOLFOX
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 6 months not reached; 3 months not reached. Survival at 3 years: 6 months 90%; 3 months 89%. Hazard ratio 6 months vs 3 months 0.87 (95% CI 0.72–1.07).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 6 months | 987 | 182 | not reached |
| 3 months | 984 | 207 | not reached |
- 6 months vs 3 months: reconstructed HR 0.87 (95% CI 0.72–1.07)
Landmark survival (reconstructed)
| Time | 6 months | 3 months |
|---|---|---|
| 1 yr | 98.0% | 97.1% |
| 2 yr | 94.4% | 93.6% |
| 3 yr | 90.1% | 89.3% |
| 5 yr | 84.1% | 82.0% |
| 7 yr | 79.7% | 77.2% |
| 10 yr | 72.2% | 67.6% |
Checks against the published figure
- hazard ratio: printed 1.1, reconstructed 1.14 pass
Overall survival — Stage III colorectal cancer, all patients (OS (stage III))
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 3 years: 3 months 89%; 6 months 89%. Hazard ratio 3 months vs 6 months 0.96 (95% CI 0.86–1.09).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 2483 | 537 | not reached |
| 6 months | 2487 | 552 | not reached |
- 3 months vs 6 months: reconstructed HR 0.96 (95% CI 0.86–1.09)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 97.3% | 97.3% |
| 2 yr | 93.6% | 93.5% |
| 3 yr | 89.1% | 88.6% |
| 5 yr | 81.0% | 81.2% |
| 7 yr | 76.3% | 75.4% |
| 10 yr | 65.5% | 62.6% |
Checks against the published figure
- hazard ratio: printed 0.97, reconstructed 0.964 pass
Overall survival — Stage III low-risk subgroup (OS (stage III low risk))
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 3 years: 3 months 96%; 6 months 94%. Hazard ratio 3 months vs 6 months 0.83 (95% CI 0.67–1.03).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 1337 | 160 | not reached |
| 6 months | 1342 | 189 | not reached |
- 3 months vs 6 months: reconstructed HR 0.83 (95% CI 0.67–1.03)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 100.0% | 98.3% |
| 2 yr | 100.0% | 96.7% |
| 3 yr | 96.2% | 94.3% |
| 5 yr | 90.9% | 88.9% |
| 7 yr | 86.4% | 84.4% |
| 10 yr | 75.3% | 73.7% |
Checks against the published figure
- hazard ratio: printed 0.87, reconstructed 0.831 pass
Overall survival — Stage III high-risk subgroup (OS (stage III high risk))
From figure panel C · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 3 years: 3 months 82%; 6 months 82%. Hazard ratio 6 months vs 3 months 0.97 (95% CI 0.84–1.12).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 1145 | 374 | not reached |
| 6 months | 1145 | 363 | not reached |
- 6 months vs 3 months: reconstructed HR 0.97 (95% CI 0.84–1.12)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 96.1% | 96.1% |
| 2 yr | 89.8% | 89.8% |
| 3 yr | 82.0% | 82.0% |
| 5 yr | 70.0% | 71.7% |
| 7 yr | 63.4% | 66.0% |
| 10 yr | 54.6% | 53.7% |
Checks against the published figure
- hazard ratio: printed 1.02, reconstructed 1.03 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- XELOX + bevacizumab ± adoptive cell immunotherapy in colorectal cancer: Overall survival; Progression-free survival
- BREAKWATER: Overall survival
- Cetuximab β + FOLFIRI in RAS/BRAF wild-type colorectal cancer: Overall survival; Progression-free survival (BIRC-assessed)
- Sequential vs upfront oxaliplatin in metastatic colorectal cancer: Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials